Current options and investigational drugs for the treatment of eosinophilic esophagitis

References

• Lucendo AJ, Molina-Infante J, Arias A, et al. Guidelines on eosinophilic esophagitis: evidence-based statements and recommendations for diagnosis and management in children and adults. United European Gastroenterol J. 2017;5:335–358. DOI:https://doi.org/10.1177/2050640616689525.
   PubMed Web of Science ®Google Scholar
• Pérez-Martínez I, Rodrigo L, and Lucendo AJ. Eosinophilic esophagitis: an evidenced-based approach to diagnosis and treatment. Med Clin (Barc). 2018 ;152:444–449. . DOI:https://doi.org/10.1016/j.medcli.2018.10.022.
   PubMed Web of Science ®Google Scholar
• Navarro P, Arias Á, and Arias-González L, et al. Systematic review with meta-analysis: the growing incidence and prevalence of eosinophilic oesophagitis in children and adults in population-based studies. Aliment Pharmacol Ther. 2019 ;49:1116–1125. . DOI:https://doi.org/10.1111/apt.15231.
   PubMed Web of Science ®Google Scholar
• Arias Á, Lucendo AJ. Incidence and prevalence of eosinophilic oesophagitis increase continuously in adults and children in Central Spain: A 12-year population-based study. Dig Liver Dis. 2019;51:55–62.
   PubMedGoogle Scholar
• Dellon ES, Hirano I. Epidemiology and natural history of eosinophilic esophagitis. Gastroente rology. 2018;154:319–332.e3. DOI:https://doi.org/10.1053/j.gastro.2017.06.067.
   PubMed Web of Science ®Google Scholar
• Dellon ES, Kim HP, Sperry SLW, et al. A phenotypic analysis shows that eosinophilic esophagitis is a progressive fibrostenotic disease. Gastrointest Endosc. 2014;79:577–585.e4.
   PubMed Web of Science ®Google Scholar
• Schoepfer AM, Safroneeva E, Bussmann C, et al. Delay in diagnosis of eosinophilic esophagitis increases risk for stricture formation in a time-dependent manner. Gastroenterology. 2013;145:1230–1236.e1–2. DOI:https://doi.org/10.1053/j.gastro.2013.08.015.
   PubMed Web of Science ®Google Scholar
• Lipka S, Kumar A, Richter JE. Impact of diagnostic delay and other risk factors on eosinophilic esophagitis phenotype and esophageal diameter. J Clin Gastroenterol. 2016;50:134–140.
   PubMed Web of Science ®Google Scholar
• Lucendo AJ, Arias-González L, Molina-Infante J, et al. Systematic review: health-related quality of life in children and adults with eosinophilic oesophagitis-instruments for measurement and determinant factors. Aliment Pharmacol Ther. 2017;46:401–409.
   PubMed Web of Science ®Google Scholar
• Kelly KJ, Lazenby AJ, Rowe PC, et al. Eosinophilic esophagitis attributed to gastroesophageal reflux: improvement with an amino acid-based formula. Gastroenterology. 1995;109:1503–1512.
   PubMed Web of Science ®Google Scholar
• Molina-Infante J, and Lucendo AJ. Dietary therapy for eosinophilic esophagitis. J Allergy Clin Immunol. 2018 ;142:41–47. . DOI:https://doi.org/10.1016/j.jaci.2018.02.028.
   PubMed Web of Science ®Google Scholar
• Philpott H, Nandurkar S, Royce SG, et al. Allergy tests do not predict food triggers in adult patients with eosinophilic oesophagitis. A comprehensive prospective study using five modalities. Aliment Pharmacol Ther. 2016;44:223–233.
   PubMed Web of Science ®Google Scholar
• Lucendo AJ. Meta-Analysis-based guidance for dietary management in eosinophilic esophagitis. Curr Gastroenterol Rep. 2015;17:464.
   PubMedGoogle Scholar
• Chuang M-YA, Chinnaratha MA, Hancock DG, et al. Topical steroid therapy for the treatment of eosinophilic esophagitis (EoE): a systematic review and meta-analysis. Clin Transl Gastroenterol. 2015;6:e82. DOI:https://doi.org/10.1038/ctg.2015.9.
   PubMed Web of Science ®Google Scholar
• Sawas T, Dhalla S, Sayyar M, et al. Systematic review with meta-analysis: pharmacological interventions for eosinophilic oesophagitis. Aliment Pharmacol Ther. 2015;41:797–806.
   PubMed Web of Science ®Google Scholar
• Murali AR, Gupta A, Attar BM, et al. Topical steroids in eosinophilic esophagitis: systematic review and meta-analysis of placebo-controlled randomized clinical trials. J Gastroenterol Hepatol. 2016;31:1111–1119.
   PubMed Web of Science ®Google Scholar
• Rokkas T, Niv Y, Malfertheiner P. A network meta-analysis of randomized controlled trials on the treatment of eosinophilic esophagitis in adults and children. J Clin Gastroenterol. 2021;55:400–410.
   PubMed Web of Science ®Google Scholar
• Dellon ES, Katzka DA, Collins MH, et al. Budesonide oral suspension improves symptomatic, endoscopic, and histologic parameters compared with placebo in patients with eosinophilic esophagitis. Gastroenterology. 2017;152:776–786.e5.
   PubMed Web of Science ®Google Scholar
• Lucendo AJ, Miehlke S, Schlag C, et al. Efficacy of budesonide orodispersible tablets as induction therapy for eosinophilic esophagitis in a randomized placebo-controlled trial. Gastroenterology. 2019;157, 74–86.e15. DOI:https://doi.org/10.1053/j.gastro.2019.03.025.
   PubMed Web of Science ®Google Scholar
• Molina-Infante J, and Lucendo AJ. Proton pump inhibitor therapy for eosinophilic esophagitis: a paradigm shift. Am J Gastroenterol. 2017 ;112:1770–1773. . DOI:https://doi.org/10.1038/ajg.2017.404.
   PubMed Web of Science ®Google Scholar
• Lucendo AJ, Arias A, Molina-Infante J. Efficacy of proton pump inhibitor drugs for inducing clinical and histologic remission in patients with symptomatic esophageal eosinophilia: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2016;14:13–22.e1. DOI:https://doi.org/10.1016/j.cgh.2015.07.041.
   PubMed Web of Science ®Google Scholar
• Molina-Infante J, Rodriguez-Sanchez J, Martinek J, et al. Long-Term loss of response in proton pump inhibitor-responsive esophageal eosinophilia is uncommon and influenced by CYP2C19 genotype and rhinoconjunctivitis. Am J Gastroenterol. 2015;110:1567–1575.
   PubMed Web of Science ®Google Scholar
• Gutiérrez-Junquera C, Fernández-Fernández S, Cilleruelo ML, et al. High prevalence of response to proton-pump inhibitor treatment in children with esophageal eosinophilia. J Pediatr Gastroenterol Nutr. 2016;62:704–710.
   PubMed Web of Science ®Google Scholar
• Gómez-Torrijos E, García-Rodríguez R, Castro-Jiménez A, et al. The efficacy of step-down therapy in adult patients with proton pump inhibitor-responsive oesophageal eosinophilia. Aliment Pharmacol Ther. 2016;43:534–540.
   PubMed Web of Science ®Google Scholar
• Molina-Infante J, Bredenoord AJ, Cheng E, et al. Proton pump inhibitor-responsive oesophageal eosinophilia: An entity challenging current diagnostic criteria for eosinophilic oesophagitis. Gut. 2016;65:521–531.
   Web of Science ®Google Scholar
• Laserna-Mendieta EJ, Casabona S, Guagnozzi D, et al. Efficacy of proton pump inhibitor therapy for eosinophilic oesophagitis in 630 patients: results from the EoE connect registry. Aliment Pharmacol Ther. 2020;52:798–807.
   PubMed Web of Science ®Google Scholar
• Moawad FJ, Molina-Infante J, and Lucendo AJ, et al. Systematic review with meta-analysis: endoscopic dilation is highly effective and safe in children and adults with eosinophilic oesophagitis. Aliment Pharmacol Ther. 2017 46: 96–105 . . DOI:https://doi.org/10.1111/apt.14123.
   Google Scholar
• Lucendo AJ, Molina-Infante J. Esophageal dilation in eosinophilic esophagitis: risks, benefits, and when to do it. Curr Opin Gastroenterol. 2018;34:226–232.
   PubMed Web of Science ®Google Scholar
• Attwood SE, Smyrk TC, Demeester TR, et al. Esophageal eosinophilia with dysphagia. a distinct clinicopathologic syndrome. Dig Dis Sci. 1993;38:109–116.
   PubMed Web of Science ®Google Scholar
• Straumann A, Spichtin HP, Bernoulli R, et al. Idiopathic eosinophilic esophagitis: a frequently overlooked disease with typical clinical aspects and discrete endoscopic findings. Schweiz Med Wochenschr. 1994;124:1419–1429.
   PubMedGoogle Scholar
• Hirano I, Chan ES, Rank MA, et al. AGA institute and the joint task force on allergy-immunology practice parameters clinical guidelines for the management of eosinophilic esophagitis. Gastroenterology. 2020;158:1776–1786.
   PubMed Web of Science ®Google Scholar
• Furuta GT, Liacouras CA, Collins MH, et al. Eosinophilic esophagitis in children and adults: a systematic review and consensus recommendations for diagnosis and treatment. Gastroenterology. 2007;133:1342–1363. DOI:https://doi.org/10.1053/j.gastro.2007.08.017.
   PubMed Web of Science ®Google Scholar
• Liacouras CA, Furuta GT, Hirano I, et al. Eosinophilic esophagitis: updated consensus recommendations for children and adults. J Allergy Clin Immunol. 2011;128:3–20.e6; quiz 21–22.
   PubMed Web of Science ®Google Scholar
• Dellon ES, Liacouras CA, and Molina-Infante J, et al. Updated international consensus diagnostic criteria for eosinophilic esophagitis. Proceedings of the AGREE Conference. Gastroenterology. 2018;155:1022-1033. DOI: https://doi.org/10.1053/j.gastro.2018.07.009.
   Google Scholar
• Peery AF, Shaheen NJ, Dellon ES. Practice patterns for the evaluation and treatment of eosinophilic oesophagitis. Aliment Pharmacol Ther. 2010;32:1373–1382.
   PubMed Web of Science ®Google Scholar
• Spergel JM, Book WM, Mays E, et al. Variation in prevalence, diagnostic criteria, and initial management options for eosinophilic gastrointestinal diseases in the United States. J Pediatr Gastroenterol Nutr. 2011;52:300–306.
   PubMed Web of Science ®Google Scholar
• Miehlke S, von Arnim U, Schlag C, et al. Clinical management of eosinophilic esophagitis - a nationwide survey among gastroenterologists in Germany. Z Gastroenterol. 2019;57:745–752.
   PubMed Web of Science ®Google Scholar
• Huang KZ, Jensen ET, Chen HX, et al. Practice pattern variation in pediatric eosinophilic esophagitis in the Carolinas EoE collaborative: a research model in community and academic practices. South Med J. 2018;111:328–332.
   PubMed Web of Science ®Google Scholar
• Laserna-Mendieta EJ, Casabona S, Savarino E, et al. Efficacy of therapy for eosinophilic esophagitis in real-world practice. Clin Gastroenterol Hepatol. 2020;18:2903–2911.e4.
   PubMed Web of Science ®Google Scholar
• Molina-Infante J, Lucendo AJ. Eosinophilic esophagitis: a practical approach to diagnosis and management. Expert Rev Gastroenterol Hepatol. 2014;8:925–934.
   PubMed Web of Science ®Google Scholar
• Ma C, Schoepfer AM, Dellon ES, et al. Development of a core outcome set for therapeutic studies in eosinophilic esophagitis (COREOS). J Allergy Clin Immunol. 2021;S0091674921010599.
   Google Scholar
• Dellon ES, and Gupta SK. A conceptual approach to understanding treatment response in eosinophilic esophagitis. Clin Gastroenterol Hepatol. . 2019 ;(11):2149–2160. DOI:https://doi.org/10.1016/j.cgh.2019.01.030.
   Google Scholar
• Lucendo AJ, Molina-Infante J. Eosinophilic oesophagitis: current evidence-based diagnosis and treatment. Gastroenterol Hepatol. 2018;41:281–291.
   PubMed Web of Science ®Google Scholar
• Lucendo AJ. Pharmacological treatments for eosinophilic esophagitis: current options and emerging therapies. Expert Rev Clin Immunol. 2020;16:63–77.
   PubMed Web of Science ®Google Scholar
• Safroneeva E, Straumann A, Coslovsky M, et al. Symptoms have modest accuracy in detecting endoscopic and histologic remission in adults with eosinophilic esophagitis. Gastroenterology. 2016;150:581–590.e4.
   PubMed Web of Science ®Google Scholar
• Lucendo AJ, Molina-Infante J. Limitation of symptoms as predictors of remission in eosinophilic esophagitis: the need to go beyond endoscopy and histology. Gastroenterology. 2016;150:547–549.
   PubMed Web of Science ®Google Scholar
• Alexander R, Alexander JA, Ravi K, et al. Measurement of observed eating behaviors in patients with active and inactive eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2019;17:2371–2373.
   PubMed Web of Science ®Google Scholar
• Larsson JK, Sonestedt E, Ohlsson B, et al. The association between the intake of specific dietary components and lifestyle factors and microscopic colitis. Eur J Clin Nutr. 2016;70:1309–1317.
   PubMed Web of Science ®Google Scholar
• Sodikoff J, Hirano I. Therapeutic strategies in eosinophilic esophagitis: Induction, maintenance and refractory disease. Best Pract Res Clin Gastroenterol. 2015;29:829–839.
   PubMed Web of Science ®Google Scholar
• Noel RJ, Putnam PE, Rothenberg ME. Eosinophilic esophagitis. N Engl J Med. 2004;351:940–941.
   PubMed Web of Science ®Google Scholar
• Lucendo AJ, Sanchez-Cazalilla M. Adult versus pediatric eosinophilic esophagitis: important differences and similarities for the clinician to understand. Expert Rev Clin Immunol. 2012;8:733–745.
   PubMed Web of Science ®Google Scholar
• Dellon ES, Irani A-M, Hill MR, et al. Development and field testing of a novel patient-reported outcome measure of dysphagia in patients with eosinophilic esophagitis. Aliment Pharmacol Ther. 2013;38:634–642.
   PubMed Web of Science ®Google Scholar
• Schoepfer AM, Straumann A, Panczak R, et al. Development and validation of a symptom-based activity index for adults with eosinophilic esophagitis. Gastroenterology. 2014;147:1255–1266.e21.
   PubMed Web of Science ®Google Scholar
• Franciosi JP, Hommel KA, DeBrosse CW, et al. Development of a validated patient-reported symptom metric for pediatric eosinophilic esophagitis: qualitative methods. BMC Gastroenterol. 2011;11:126.
   PubMed Web of Science ®Google Scholar
• Schoepfer AM, Panczak R, Zwahlen M, et al. How do gastroenterologists assess overall activity of eosinophilic esophagitis in adult patients? Am J Gastroenterol. 2015;110:402–414.
   PubMed Web of Science ®Google Scholar
• Reed CC, Wolf WA, Cotton CC, et al. Optimal histologic cutpoints for treatment response in patients with eosinophilic esophagitis: analysis of data from a prospective cohort study. Clin Gastroenterol Hepatol. 2018;16:226–233.e2.
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health and Human Services. Food and drug administration, center for drug evaluation and research (CDER). Eosinophilic esophagitis: developing drugs for treatment guidance for industry. 2020; [cited 2020 Nov 22] https://www.fda.gov/media/120089/download
   Google Scholar
• Collins MH, Martin LJ, Alexander ES, et al. Newly developed and validated eosinophilic esophagitis histology scoring system and evidence that it outperforms peak eosinophil count for disease diagnosis and monitoring. Dis Esophagus. 2017;30:1–8. DOI:https://doi.org/10.1111/dote.12470.
   PubMed Web of Science ®Google Scholar
• Lin B, Rabinowitz S, Haseeb MA, et al. Usefulness of the eosinophilic esophagitis histologic scoring system in distinguishing active eosinophilic esophagitis from remission and gastroesophageal reflux disease. Gastroenterology Research. 2021;14(4):220–226. DOI:https://doi.org/10.14740/gr1423.
   PubMed Web of Science ®Google Scholar
• Warners MJ, Ambarus CA, Bredenoord AJ, et al. Reliability of histologic assessment in patients with eosinophilic oesophagitis. Aliment Pharmacol Ther. 2018;47(7):940–950. DOI:https://doi.org/10.1111/apt.14559.
   PubMed Web of Science ®Google Scholar
• Hirano I, Collins MH, Assouline-Dayan Y, et al. RPC4046, a monoclonal antibody against IL13, reduces histologic and endoscopic activity in patients with eosinophilic esophagitis. Gastroenterology. 2019;156:592–603.e10. DOI:https://doi.org/10.1053/j.gastro.2018.10.051.
   PubMed Web of Science ®Google Scholar
• Hirano I, Moy N, Heckman MG, et al. Endoscopic assessment of the oesophageal features of eosinophilic oesophagitis: Validation of a novel classification and grading system. Gut. 2013;62(4):489–495. DOI:https://doi.org/10.1136/gutjnl-2011-301817.
   PubMed Web of Science ®Google Scholar
• Yoon HJ, Youn YH, Park JC, et al. Reversibility of endoscopic features after treatment for eosinophilic esophagitis. Yonsei Med J. 2021;62(6):487–493. DOI:https://doi.org/10.3349/ymj.2021.62.6.487.
   PubMed Web of Science ®Google Scholar
• Lin Z, Kahrilas PJ, Xiao Y, et al. Functional luminal imaging probe topography: an improved method for characterizing esophageal distensibility in eosinophilic esophagitis. Therap Adv Gastroenterol. 2013;6:97–107.
   PubMed Web of Science ®Google Scholar
• Min S, Shoda T, Wen T, et al. Diagnostic merits of the eosinophilic esophagitis diagnostic panel from a single esophageal biopsy. J Allergy Clin Immunol. 2021;S0091-6749(21):1206–1209.
   Google Scholar
• Arias A, Gonzalez-Cervera J, Tenias JM, et al. Efficacy of dietary interventions for inducing histologic remission in patients with eosinophilic esophagitis: a systematic review and meta-analysis. Gastroenterology. 2014;146:1639–1648.
   PubMed Web of Science ®Google Scholar
• Rank MA, Sharaf RN, and Furuta GT, et al. AGA institute. Technical review on the management of eosinophilic esophagitis: a report From the AGA institute and the joint task force on allergy-immunology practice parameters. Gastroenterology. 2020 ;158(6):1789–1810.
   PubMed Web of Science ®Google Scholar
• Molina-Infante J, Arias A, Barrio J, et al. Four-food group elimination diet for adult eosinophilic esophagitis: A prospective multicenter study. J Allergy Clin Immunol. 2014;134:1093–1099.e1.
   PubMed Web of Science ®Google Scholar
• Kagalwalla AF, Wechsler JB, and Amsden K, et al. Efficacy of a 4-Food elimination diet for children with eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2017 ;15:1698–1707.e7. . DOI:https://doi.org/10.1016/j.cgh.2017.05.048.
   PubMed Web of Science ®Google Scholar
• Molina-Infante J, Arias Á, Alcedo J, et al. Step-up empiric elimination diet for pediatric and adult eosinophilic esophagitis: The 2-4-6 study. J Allergy Clin Immunol. 2018;141:1365–1372.
   PubMed Web of Science ®Google Scholar
• Reed CC, Fan C, Koutlas NT, et al. Food elimination diets are effective for long-term treatment of adults with eosinophilic oesophagitis. Aliment Pharmacol Ther. 2017;46:836–844.
   PubMed Web of Science ®Google Scholar
• Wang R, Hirano I, and Doerfler B, et al. Assessing adherence and barriers to long-term elimination diet therapy in adults with eosinophilic esophagitis. Dig Dis Sci. 2018 ;(7):1756–1762. . DOI:https://doi.org/10.1007/s10620-018-5045-0
   Google Scholar
• Philpott H, Nandurkar S, Royce SG, et al. A prospective open clinical trial of a proton pump inhibitor, elimination diet and/or budesonide for eosinophilic oesophagitis. Aliment Pharmacol Ther. 2016;43:985–993.
   PubMed Web of Science ®Google Scholar
• Cury EK, Schraibman V, Faintuch S. Eosinophilic infiltration of the esophagus: gastroesophageal reflux versus eosinophilic esophagitis in children–discussion on daily practice. J Pediatr Surg. 2004;39:e4–7.
   PubMed Web of Science ®Google Scholar
• Ngo P, Furuta GT, Antonioli DA, et al. Eosinophils in the esophagus–peptic or allergic eosinophilic esophagitis? Case series of three patients with esophageal eosinophilia. Am J Gastroenterol. 2006;101:1666–1670.
   PubMed Web of Science ®Google Scholar
• Sayej WN, Patel R, Baker RD, et al. Treatment with high-dose proton pump inhibitors helps distinguish eosinophilic esophagitis from noneosinophilic esophagitis. J Pediatr Gastroenterol Nutr. 2009;49:393–399.
   PubMed Web of Science ®Google Scholar
• Molina-Infante J, Rivas MD, Hernandez-Alonso M, et al. Proton pump inhibitor-responsive oesophageal eosinophilia correlates with downregulation of eotaxin-3 and Th2 cytokines overexpression. Aliment Pharmacol Ther. 2014;40:955–965. DOI:https://doi.org/10.1111/apt.12914.
   PubMed Web of Science ®Google Scholar
• Wen T, Dellon ES, Moawad FJ, et al. Transcriptome analysis of proton pump inhibitor-responsive esophageal eosinophilia reveals proton pump inhibitor-reversible allergic inflammation. J Allergy Clin Immunol. 2015;135:187–197.
   PubMed Web of Science ®Google Scholar
• Nassar Y, Richter S. Proton-pump inhibitor use and fracture risk: an updated systematic review and meta-analysis. J Bone Metab. 2018;25:141–151.
   PubMedGoogle Scholar
• Sun J, Sun H, Cui M, et al. The use of anti-ulcer agents and the risk of chronic kidney disease: a meta-analysis. Int Urol Nephrol. 2018;50:1835–1843.
   PubMed Web of Science ®Google Scholar
• Vaezi MF, Yang Y-X, Howden CW. Complications of proton pump inhibitor therapy. Gastroenterology. 2017;153(1):35–48.
   PubMed Web of Science ®Google Scholar
• Faubion WA, Perrault J, Burgart LJ, et al. Treatment of eosinophilic esophagitis with inhaled corticosteroids. J Pediatr Gastroenterol Nutr. 1998;27:90–93.
   PubMed Web of Science ®Google Scholar
• Dellon ES, Sheikh A, Speck O, et al. Viscous topical is more effective than nebulized steroid therapy for patients with eosinophilic esophagitis. Gastroenterology. 2012;143:321–324.e1. DOI:https://doi.org/10.1053/j.gastro.2012.04.049.
   PubMed Web of Science ®Google Scholar
• Miehlke S, Lucendo AJ, Straumann A, et al. Orodispersible budesonide tablets for the treatment of eosinophilic esophagitis: a review of the latest evidence. Therap Adv Gastroenterol. 2020;13:175628482092728.
   Web of Science ®Google Scholar
• Tan ND, Xiao YL, Chen MH. Steroids therapy for eosinophilic esophagitis: systematic review and meta-analysis. J Dig Dis. 2015;16:431–442.
   PubMed Web of Science ®Google Scholar
• Greuter T, Bussmann C, Safroneeva E, et al. Long-Term treatment of eosinophilic esophagitis with swallowed topical corticosteroids: development and evaluation of a therapeutic concept. Am J Gastroenterol. 2017;112:1527–1535. DOI:https://doi.org/10.1038/ajg.2017.202.
   PubMed Web of Science ®Google Scholar
• Straumann A, Lucendo AJ, and Miehlke S, et al. Budesonide orodispersible tablets maintain remission in a randomized, placebo-controlled trial of patients with eosinophilic esophagitis. Gastroenterology. 2020 ;159:1672–1685.e5. . DOI:https://doi.org/10.1053/j.gastro.2020.07.039.
   PubMed Web of Science ®Google Scholar
• Philpott H, Dougherty MK, Reed CC, et al. Systematic review: adrenal insufficiency secondary to swallowed topical corticosteroids in eosinophilic oesophagitis. Aliment Pharmacol Ther. 2018;47(8):1071–1078. DOI:https://doi.org/10.1111/apt.14573.
   PubMed Web of Science ®Google Scholar
• Lindqvist A, Karjalainen E-M, Laitinen LA, et al. Salmeterol resolves airway obstruction but does not possess anti-eosinophil efficacy in newly diagnosed asthma: a randomized, double-blind, parallel group biopsy study comparing the effects of salmeterol, fluticasone propionate, and disodium cromoglycate. J Allergy Clin Immunol. 2003, 112 (1):23–28. DOI:https://doi.org/10.1067/mai.2003.1500.
   PubMed Web of Science ®Google Scholar
• Liacouras CA, Spergel JM, Ruchelli E, et al. Eosinophilic esophagitis: a 10-year experience in 381 children. Clin Gastroenterol Hepatol. 2005;3(12):1198–1206. DOI:https://doi.org/10.1016/S1542-3565(05)00885-2.
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Zhang J, Whitworth J, et al. A randomized, double-blinded, placebo-controlled study of the use of viscous oral cromolyn sodium for the treatment of eosinophilic esophagitis. Ann Allergy Asthma Immunol. 2018;120(5):527–531. DOI:https://doi.org/10.1016/j.anai.2018.03.006.
   PubMed Web of Science ®Google Scholar
• Cikler E, Ersoy Y, Cetinel S, et al. The leukotriene d4 receptor antagonist, montelukast, inhibits mast cell degranulation in the dermis induced by water avoidance stress. Acta Histochem. 2009;111(2):112–118. DOI:https://doi.org/10.1016/j.acthis.2008.04.006.
   PubMed Web of Science ®Google Scholar
• Ersoy Y, Cikler E, Cetinel S, et al. Leukotriene D4 receptor antagonist montelukast alleviates water avoidance stress-induced degeneration of the gastrointestinal mucosa. Prostaglandins Leukot Essent Fatty Acids. 2008;78(3):189–197. DOI:https://doi.org/10.1016/j.plefa.2008.01.007.
   PubMed Web of Science ®Google Scholar
• Stumphy J, Al-Zubeidi D, Guerin L, et al. Observations on use of montelukast in pediatric eosinophilic esophagitis: insights for the future. Dis Esophagus. 2011;24(4):229–234. DOI:https://doi.org/10.1111/j.1442-2050.2010.01134.x.
   PubMed Web of Science ®Google Scholar
• Lucendo AJ, De Rezende LC, Jimenez-Contreras S, et al. Montelukast was inefficient in maintaining steroid-induced remission in adult eosinophilic esophagitis. Dig Dis Sci. 2011;56(12):3551–3558. DOI:https://doi.org/10.1007/s10620-011-1775-y.
   PubMed Web of Science ®Google Scholar
• Alexander JA, Ravi K, Enders FT, et al. Montelukast does not maintain symptom remission after topical steroid therapy for eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2017;15(2):214–221. DOI:https://doi.org/10.1016/j.cgh.2016.09.013.
   PubMed Web of Science ®Google Scholar
• Beveridge C, Falk GW. Novel therapeutic approaches to eosinophilic esophagitis. Gastroenterol Hepatol. 2020;16:294–301.
   Google Scholar
• Savarino V, Antonioli L, Fornai M, et al. An update of pharmacology, efficacy, and safety of vonoprazan in acid-related disorders. Expert Rev Gastroenterol Hepatol. 2021 Sep 29;1–10. DOI:https://doi.org/10.1080/17474124.2021.1984878
   Google Scholar
• Martinucci I, Blandizzi C, Bodini G, et al. Vonoprazan fumarate for the management of acid-related diseases. Expert Opin Pharmacother. 2017 Aug;18(11):1145–1152.
   PubMed Web of Science ®Google Scholar
• Kuzumoto T, Tanaka F, and Sawada A, et al. Vonoprazan shows efficacy similar to that of proton pump inhibitors with respect to symptomatic, endoscopic, and histological responses in patients with eosinophilic esophagitis. Esophagus. 2021 ;18(2):372–379.
   PubMed Web of Science ®Google Scholar
• Ishimura N, and Kinoshita Y. Eosinophilic esophagitis in Japan: focus on response to acid suppressive therapy. Ishimura N, Kinoshita Y. J Gastroenterol Hepatol. 2018 ;33(5):1016–1022.
   PubMed Web of Science ®Google Scholar
• Okimoto E, Ishimura N, Ishihara S. Clinical characteristics and treatment outcomes of patients with eosinophilic esophagitis and eosinophilic gastroenteritis. Digestion. 2021;102(1):33–40.
   PubMed Web of Science ®Google Scholar
• Hirano I, Collins MH, Katzka DA, et al. Budesonide oral suspension improves outcomes in patients with eosinophilic esophagitis: results from a phase 3 trial. Clin Gastroenterol Hepatol. 2021;S1542356521004560.
   Web of Science ®Google Scholar
• Dellon ES, Collins MH, Katzka DA, et al. Long-Term treatment of eosinophilic esophagitis with budesonide oral suspension. Clin Gastroenterol Hepatol. 2021;S1542-3565(21):684.
   Google Scholar
• Hirano I, Safroneeva E, Roumet MC, et al. Randomised clinical trial: the safety and tolerability of fluticasone propionate orally disintegrating tablets versus placebo for eosinophilic oesophagitis. Aliment Pharmacol Ther. 2020;51:750–759.
   PubMed Web of Science ®Google Scholar
• Dellon ES, Lucendo AJ, Schlag C, et al. Safety and efficacy of 4 dosage regimens of APT-1011: results from a phase 2b randomized double blind placebo-controlled trial to select the best dosage regimen for further development. United European Gastroenterol J. 2019. https://ueg.eu/library/safety-and-efficacy-of-4-dosage-regimens-of-apt-1011-results-from-a-phase-2b-randomized-double-blind-placebo-controlled-trial-to-select-the-best-dosage-regimen-for-further-development-clinicaltrialsgov-nct03191864-eudract-number-2016-004749-10/208594.
   Google Scholar
• Rosenbaum C, Grimm M, Krause J, et al. Functionality and acceptance of the EsoCap System-A novel film-based drug delivery technology: results of an in Vivo study. Pharmaceutics. 2021;13:828.
   PubMed Web of Science ®Google Scholar
• Straumann A, Bauer M, Fischer B, et al. Idiopathic eosinophilic esophagitis is associated with a T(H)2-type allergic inflammatory response. J Allergy Clin Immunol. 2001;108:954–961.
   PubMed Web of Science ®Google Scholar
• Arias Á, Lucendo AJ. Molecular basis and cellular mechanisms of eosinophilic esophagitis for the clinical practice. Expert Rev Gastroenterol Hepatol. 2019;13:99–117.
   PubMed Web of Science ®Google Scholar
• Luo Y, Alexander M, Gadina M, et al. JAK-STAT signaling in human disease: from genetic syndromes to clinical inhibition. J Allergy Clin Immunol. 2021;148:911–925.
   PubMed Web of Science ®Google Scholar
• Rochman M, Azouz NP, Rothenberg ME. Epithelial origin of eosinophilic esophagitis. J Allergy Clin Immunol. 2018;142:10–23.
   PubMed Web of Science ®Google Scholar
• Matucci A, Vivarelli E, Nencini F, et al. Strategies targeting Type 2 inflammation: from monoclonal antibodies to JAK-inhibitors. Biomedicines. 2021;9:1497.
   PubMed Web of Science ®Google Scholar
• Noti M, Wojno EDT, Kim BS, et al. Thymic stromal lymphopoietin-elicited basophil responses promote eosinophilic esophagitis. Nat Med. 2013;19:1005–1013.
   PubMed Web of Science ®Google Scholar
• McBrien CN, Menzies-Gow A. The biology of eosinophils and their role in asthma. Front Med (Lausanne). 2017;4:93.
   PubMed Web of Science ®Google Scholar
• Holguin F, Cardet JC, Chung KF, et al. Management of severe asthma: a European Respiratory Society/American thoracic society guideline. Eur Respir J. 2020;55:1900588.
   PubMed Web of Science ®Google Scholar
• Farne HA, Wilson A, Powell C, et al. Anti-IL5 therapies for asthma. Cochrane Database Syst Rev. 2017;9;CD010834. DOI:https://doi.org/10.1002/14651858.CD010834.pub3.
   PubMed Web of Science ®Google Scholar
• Bachert C, Sousa AR, Lund VJ, et al. Reduced need for surgery in severe nasal polyposis with mepolizumab: randomized trial. J Allergy Clin Immunol. 2017;140:1024–1031.e14.
   PubMed Web of Science ®Google Scholar
• Yamazaki K, Murray JA, Arora AS, et al. Allergen-specific in vitro cytokine production in adult patients with eosinophilic esophagitis. Dig Dis Sci. 2006;51:1934–1941.
   PubMed Web of Science ®Google Scholar
• Straumann A, Conus S, Grzonka P, et al. Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: A randomised, placebo-controlled, double-blind trial. Gut. 2010;59:21–30.
   PubMed Web of Science ®Google Scholar
• Assa’ad AH, Gupta SK, Collins MH, et al. An antibody against IL-5 reduces numbers of esophageal intraepithelial eosinophils in children with eosinophilic esophagitis. Gastroenterology. 2011;141:1593–1604.
   PubMed Web of Science ®Google Scholar
• Spergel JM, Rothenberg ME, Collins MH, et al. Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial. J Allergy Clin Immunol. 2012;129:456–463, 463.e1–3.
   Web of Science ®Google Scholar
• Markowitz JE, Jobe L, Miller M, et al. Safety and efficacy of reslizumab for children and adolescents with eosinophilic esophagitis treated for 9 years. J Pediatr Gastroenterol Nutr. 2018;66:893–897.
   PubMed Web of Science ®Google Scholar
• Ghazi A, Trikha A, Calhoun WJ. Benralizumab–a humanized mAb to IL-5Rα with enhanced antibody-dependent cell-mediated cytotoxicity–a novel approach for the treatment of asthma. Expert Opin Biol Ther. 2012;12:113–118.
   PubMed Web of Science ®Google Scholar
• Di Bona D, Crimi C, and D’Uggento AM, et al. Effectiveness of benralizumab in severe eosinophilic asthma: distinct sub-phenotypes of response identified by cluster analysis. Clin Exp Allergy. 2021 . . DOI:https://doi.org/10.1111/cea.14026.
   Google Scholar
• Kuang FL, Legrand F, Makiya M, et al. Benralizumab for PDGFRA-Negative hypereosinophilic syndrome. N Engl J Med. 2019;380:1336–1346.
   PubMed Web of Science ®Google Scholar
• Wenzel AA, Wadhwani N, Wechsler JB. Continued basal zone expansion after resolution of eosinophilia in a child with eosinophilic esophagitis on benralizumab. J Pediatr Gastroenterol Nutr. 2021 Oct 5. Epub ahead of print. DOI:https://doi.org/10.1097/MPG.0000000000003319.
   Google Scholar
• Marone G, Granata F, Pucino V, et al. The intriguing role of interleukin 13 in the pathophysiology of asthma. Front Pharmacol. 2019;10:1387.
   PubMed Web of Science ®Google Scholar
• Hanania NA, Korenblat P, Chapman KR, et al. Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respir Med. 2016;4:781–796.
   PubMed Web of Science ®Google Scholar
• Panettieri RA, Sjöbring U, Péterffy A, et al. Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials. Lancet Respir Med. 2018;6:511–525.
   PubMed Web of Science ®Google Scholar
• De Boever EH, Ashman C, Cahn AP, et al. Efficacy and safety of an anti-IL-13 mAb in patients with severe asthma: a randomized trial. J Allergy Clin Immunol. 2014;133:989–996.
   PubMed Web of Science ®Google Scholar
• Neilsen CV, Bryce PJ. Interleukin-13 directly promotes oesophagus production of CCL11 and CCL24 and the migration of eosinophils. Clin Exp Immunol. 2010;40:427–434.
   Google Scholar
• Rothenberg ME, Wen T, Greenberg A, et al. Intravenous anti-IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis. J Allergy Clin Immunol. 2015;135:500–507.
   PubMed Web of Science ®Google Scholar
• Dellon ES, Collins MH, Rothenberg ME, et al. Long-term efficacy and tolerability of RPC4046 in an open-label extension trial of patients with eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2021;19(3):473–483.e17. DOI:https://doi.org/10.1016/j.cgh.2020.03.036.
   PubMed Web of Science ®Google Scholar
• Schmid-Grendelmeier P, Altznauer F, Fischer B, et al. Eosinophils express functional IL-13 in eosinophilic inflammatory diseases. J Immunol. 2002;169:1021–1027.
   PubMed Web of Science ®Google Scholar
• Vatrella A, Fabozzi I, Calabrese C, et al. Dupilumab: a novel treatment for asthma. J Asthma Allergy. 2014;7:123–130.
   PubMedGoogle Scholar
• Wenzel SE, Wang L, Pirozzi G. Dupilumab in persistent asthma. N Engl J Med. 2013;369:1276.
   PubMed Web of Science ®Google Scholar
• Beck LA, Thaçi D, Hamilton JD, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014;371:130–139.
   PubMed Web of Science ®Google Scholar
• Fokkens W, Van Der Lans R, Reitsma S. Dupilumab for the treatment of chronic rhinosinusitis with nasal polyposis. Expert Opin Biol Ther. 2021;21:575–585.
   PubMed Web of Science ®Google Scholar
• Hirano I, Dellon ES, Hamilton JD, et al. Efficacy of dupilumab in a phase 2 randomized trial of adults with active eosinophilic esophagitis. Gastroenterology. 2020;158:111–122.e10. DOI:https://doi.org/10.1053/j.gastro.2019.09.042.
   PubMed Web of Science ®Google Scholar
• Straumann A, Conus S, Degen L, et al. Budesonide is effective in adolescent and adult patients with active eosinophilic esophagitis. Gastroenterology. 2010;139:1526–1537. 1. DOI: https://doi.org/10.1053/j.gastro.2010.07.048.
   PubMed Web of Science ®Google Scholar
• Hudgens S, Evans C, Phillips E, et al. Psychometric validation of the dysphagia symptom questionnaire in patients with eosinophilic esophagitis treated with budesonide oral suspension. J Patient Rep Outcomes. 2017;1:3. DOI: https://doi.org/10.1186/s41687-017-0006-5.
   PubMedGoogle Scholar
• Dellon ES. Dupilumab for EoE at ACG 2021. 2021; [cited 2021 Oct 21]. https://www.hcplive.com/view/dellon-dupilumab-eoe-acg-2021
   Google Scholar
• Porsbjerg CM, Sverrild A, Lloyd CM, et al. Anti-alarmins in asthma: targeting the airway epithelium with next-generation biologics. Eur Respir J. 2020;56:2000260.
   PubMed Web of Science ®Google Scholar
• Wang W, Li Y, Lv Z, et al. Bronchial allergen challenge of patients with atopic asthma triggers an alarmin (IL-33, TSLP, and IL-25) response in the airways epithelium and submucosa. JI. 2018;201:2221–2231.
   Google Scholar
• Corren J, Parnes JR, Wang L, et al. Tezepelumab in adults with uncontrolled asthma. N Engl J Med. 2017;377:936–946.
   PubMed Web of Science ®Google Scholar
• Salas A, Hernandez-Rocha C, Duijvestein M, et al. JAK–STAT pathway targeting for the treatment of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2020;17:323–337.
   PubMed Web of Science ®Google Scholar
• Lin Y-J, Anzaghe M, Schülke S. Update on the pathomechanism, diagnosis, and treatment options for rheumatoid arthritis. Cells. 2020;9:E880.
   PubMed Web of Science ®Google Scholar
• Georas SN, Donohue P, Connolly M, et al. JAK inhibitors for asthma. J Allergy Clin Immunol. 2021;148:953–963.
   PubMed Web of Science ®Google Scholar
• Calbet M, Ramis I, Calama E, et al. Novel inhaled Pan-JAK inhibitor, LAS194046, reduces allergen-induced airway inflammation, late asthmatic response, and pSTAT activation in Brown Norway rats. J Pharmacol Exp Ther. 2019;370:137–147.
   PubMed Web of Science ®Google Scholar
• Cheng E, Zhang X, Wilson KS, et al. JAK-STAT6 pathway inhibitors block Eotaxin-3 secretion by epithelial cells and fibroblasts from esophageal eosinophilia patients: promising agents to improve inflammation and prevent fibrosis in EoE. PLoS ONE. 2016;11:e0157376.
   PubMed Web of Science ®Google Scholar
• Mendoza Alvarez LB, Liu X, and Glover S. Treatment-resistant eosinophilic oesophagitis successfully managed with tofacitinib. BMJ Case Rep. 2019 ;12, . DOI:https://doi.org/10.1136/bcr-2019-232558.
   Google Scholar
• Laura A. Lucaciu 1, Nathan Constantine-Cooke 2, Nikolas Plevris 1, Spyros Siakavellas 1, Lauranne A A P Derikx 1, Gareth-Rhys Jones 1, Charles W Lees 3. Real-world experience with tofacitinib in ulcerative colitis: a systematic review and meta-analysis. Therap Adv Gastroenterol. 2021 Dec 23;14:17562848211064004. DOI:https://doi.org/10.1177/17562848211064004.
   Web of Science ®Google Scholar
• Burmester GR, Winthrop K, Blanco R, et al. Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 Trials. Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: an integrated analysis of two pivotal Phase 3 trials. Rheumatol Ther. 2021;30:1–19.
   Google Scholar
• Taneja V, El-Dallal M, Haq Z, et al. Effectiveness and safety of tofacitinib for ulcerative colitis: systematic review and meta-analysis. J Clin Gastroenterol. 2021 Sep 9. DOI: https://doi.org/10.1097/MCG.0000000000001608.
   Google Scholar
• Alves C, Penedones A, Mendes D, et al. Risk of cardiovascular and venous thromboembolic events associated With Janus Kinase inhibitors in rheumatoid arthritis: a systematic review and network meta-analysis. J Clin Rheumatol. 2021 Nov 3. DOI: https://doi.org/10.1097/RHU.0000000000001804.
   Google Scholar
• Bryan AM, Del Poeta M. Sphingosine-1-phosphate receptors and innate immunity. Cell Microbiol. 2018;20:e12836.
   PubMed Web of Science ®Google Scholar
• Pérez-Jeldres T, Alvarez-Lobos M, Rivera-Nieves J. Targeting Sphingosine-1-Phosphate signaling in Immune-Mediated diseases: beyond multiple sclerosis. Drugs. 2021;81:985–1002.
   PubMed Web of Science ®Google Scholar
• Kiwamoto T, Kawasaki N, Paulson JC, et al. Siglec-8 as a drugable target to treat eosinophil and mast cell-associated conditions. Pharmacol Ther. 2012;135:327–336.
   PubMed Web of Science ®Google Scholar
• Dellon ES, Peterson KA, Murray JA, et al. Anti-Siglec-8 Antibody for Eosinophilic Gastritis and Duodenitis. N Engl J Med. 2020;383:1624–1634.
   PubMed Web of Science ®Google Scholar
• Blanchard C, Wang N, Stringer KF, et al. Eotaxin-3 and a uniquely conserved gene-expression profile in eosinophilic esophagitis. J Clin Invest. 2006;116:536–547.
   PubMed Web of Science ®Google Scholar
• Song DJ, Shim MH, Lee N, et al. CCR3 Monoclonal Antibody Inhibits Eosinophilic Inflammation and Mucosal Injury in a Mouse Model of Eosinophilic Gastroenteritis. Allergy Asthma Immunol Res. 2017;9:360–367.
   PubMed Web of Science ®Google Scholar
• Neighbour H, Boulet L-P, Lemiere C, et al. Safety and efficacy of an oral CCR3 antagonist in patients with asthma and eosinophilic bronchitis: a randomized, placebo-controlled clinical trial. Clin Exp Allergy. 2014;44:508–516.
   PubMed Web of Science ®Google Scholar
• Odiase E, Zhang X, Chang Y, et al. L-type calcium channel inhibitors (verapamil and diltiazem) block Th2-cytokine-stimulated eotaxin-3 secretion in esophageal squamous cells from patients with eosinophilic esophagitis. Gastroenterology. 2019;156:S–39.
   Google Scholar
• Odiase E, Zhang X, Chang Y, et al. In Esophageal Squamous Cells From Eosinophilic Esophagitis Patients, Th2 Cytokines Increase Eotaxin-3 Secretion Through Effects on Intracellular Calcium and a Non-Gastric Proton Pump. Gastroenterology. 2021;160:2072–2088.e6.
   PubMed Web of Science ®Google Scholar
• Cheng E, Souza RF, Spechler SJ. Tissue remodeling in eosinophilic esophagitis. Am J Physiol Gastrointest Liver Physiol. 2012;303:G1175–1187.
   PubMed Web of Science ®Google Scholar
• Aceves SS, Newbury RO, Chen D, et al. Resolution of remodeling in eosinophilic esophagitis correlates with epithelial response to topical corticosteroids. Allergy. 2010;65:109–116.
   PubMed Web of Science ®Google Scholar
• Aceves SS, Newbury RO, Dohil R, et al. Esophageal remodeling in pediatric eosinophilic esophagitis. J Allergy Clin Immunol. 2007;119:206–212.
   PubMed Web of Science ®Google Scholar
• Mishra A, Wang M, Pemmaraju VR, et al. Esophageal remodeling develops as a consequence of tissue specific IL-5-induced eosinophilia. Gastroenterology. 2008;134:204–214.
   PubMed Web of Science ®Google Scholar
• Carlson DA, Hirano I, Zalewski A, et al. Improvement in esophageal distensi- bility in response to medical and diet therapy in eosinophilic esophagitis. Clin Transl Gastroenterol. 2017;8:e119.
   PubMed Web of Science ®Google Scholar
• Navarro P, Laserna-Mendieta EJ, and Guagnozzi D, et al. Proton pump inhibitor therapy reverses endoscopic features of fibrosis in eosinophilic esophagitis. Dig Liver Dis. 2021 ;53(11):1479–1485. DOI:https://doi.org/10.1016/j.dld.2021.05.025.
   PubMedGoogle Scholar
• Lucendo AJ, Schlag C, Straumann A, et al.; Budesonide orodispersible tablets improve the esophageal distensibility in eosinophilic esophagitis: results from subset analysis of the randomized, double-blind, multicenter, placebo-controlled EOS-1 and EOS-2 trials. United European Gastroenterology J. 2021;9(S8):133.
   Google Scholar
• Hirano I, Spechler S, Furuta G, et al. White paper AGA: drug development for eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2017;15:1173–1183.
   PubMed Web of Science ®Google Scholar
• Cotton CC, Durban R, Dellon ES. Illuminating elimination diets: controversies regarding dietary treatment of eosinophilic esophagitis. Dig Dis Sci. 2019;64:1401–1408.
   PubMed Web of Science ®Google Scholar
• de Rooij We, Dellon ES, and Parker CE, et al. Pharmacotherapies for the treatment of eosinophilic esophagitis: state of the art review. Drugs. 2019 79 13 1419–1434 . . DOI: https://doi.org/10.1007/s40265-019-01173-2
   PubMed Web of Science ®Google Scholar
• Loke YK, Gilbert D, Thavarajah M, et al. Bone mineral density and fracture risk with long-term use of inhaled corticosteroids in patients with asthma: systematic review and meta-analysis. BMJ Open. 2015;5:e008554.
   PubMed Web of Science ®Google Scholar
• Yeo S-H, Aggarwal B, Shantakumar S, et al. Efficacy and safety of inhaled corticosteroids relative to fluticasone propionate: a systematic review of randomized controlled trials in asthma. Expert Rev Respir Med. 2017;11:763–778.
   PubMed Web of Science ®Google Scholar
• Cross RK. Safety Considerations with the Use of Corticosteroids and Biologic Therapies in Mild-to-Moderate Ulcerative Colitis. Inflamm Bowel Dis. 2017;23:1689–1701.
   PubMed Web of Science ®Google Scholar
• Aranez V, and Ambrus J. Immunologic Adverse Effects of Biologics for the Treatment of Atopy. Clin Rev Allergy Immunol. 2020 59 2 220–230 . . DOI:https://doi.org/10.1007/s12016-019-08739-8.
   PubMed Web of Science ®Google Scholar
• González-Cervera J, Arias Á, Redondo-González O, et al. Association between atopic manifestations and eosinophilic esophagitis: a systematic review and meta-analysis. Ann Allergy Asthma Immunol. 2017;118:582–590.e2.
   PubMed Web of Science ®Google Scholar
• Dellon ES. Cost-effective care in eosinophilic esophagitis. Ann Allergy Asthma Immunol. 2019;123:166–172.
   PubMed Web of Science ®Google Scholar
• Anderson J, Moonie S, Hogan MB, et al. Cost of chronic inflammatory disease: the impact of eosinophilic esophagitis in Nevada. J Dig Dis. 2020;21:12–19.
   PubMed Web of Science ®Google Scholar
• Eke R, Dellon ES. Hospitalization trends and determinants of inpatient costs for eosinophilic esophagitis patients in the United States: results from the Nationwide Inpatient Sample analysis. Ann Gastroenterol. 2021;34:643–650.
   PubMed Web of Science ®Google Scholar
• Beauchemin C, Castonguay A, Chan ES, et al. Economic evaluation of budesonide orodispersible tablets for the treatment of eosinophilic esophagitis: a cost-utility analysis. Adv Ther. 2021 Oct 26;38:5737–5751. Epub ahead of print. DOI:https://doi.org/10.1007/s12325-021-01957-7.
   PubMed Web of Science ®Google Scholar